CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 585 enrolled
Drug / intervention
bimatoprost 0.03%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01623479
NCT01623479N/ACompleted

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Allergan·observational·Posted Jun 20, 2012·Updated Apr 16, 2019

In Brief

An observational study evaluating bimatoprost 0.03% for Eyelash Hypotrichosis. Completed, enrolled 585 participants across 1 site.

Detailed Summary

This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 20, 2012
Enrollment StartNov 19, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.0 years ago

Interventions

bimatoprost 0.03%drug

Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months